Citations (43)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Marta C. Nunes & Shabir A. Madhi. (2012) Safety, immunogenicity and efficacy of pneumococcal conjugate vaccine in HIV-infected individuals. Human Vaccines & Immunotherapeutics 8:2, pages 161-173.
Read now
Read now
G Almroth, F Uhlin, B Ekermo, B Isaksson, B Kaijser, B Andersson, M Hahn-Zoric & M Sällberg. (2003) Perspectives on Hepatitis B Infections and the Efficacy of Vaccination (Hepatitis B and Pneumococci) in Dialysis Patients. Upsala Journal of Medical Sciences 108:1, pages 61-74.
Read now
Read now
Articles from other publishers (41)
John D. Grabenstein & Daniel M. Musher. 2023. Plotkin's Vaccines. Plotkin's Vaccines
869
889.e12
.
Maxim O. Zolotov. (2020) Peculiarities of bacterial agents of pneumonia in HIV-infected patients. Preventive measures for pulmonary infections in immunocompromised patients (literature review). Aspirantskiy Vestnik Povolzhiya 19:5-6, pages 109-115.
Crossref
Crossref
John D. Grabenstein & Daniel M. Musher. 2018. Plotkin's Vaccines. Plotkin's Vaccines
816
840.e13
.
Paratosh Prasad & John Treanor. 2018. Management of Infections in the Immunocompromised Host. Management of Infections in the Immunocompromised Host
359
374
.
Aristine Cheng, Sui-Yuan Chang, Mao-Song Tsai, Yi-Ching Su, Wen-Chun Liu, Hsin-Yun Sun & Chien-Ching Hung. (2016) Long-term immune responses and comparative effectiveness of one or two doses of 7-valent pneumococcal conjugate vaccine (PCV7) in HIV-positive adults in the era of combination antiretroviral therapy. Journal of the International AIDS Society 19:1, pages 20631.
Crossref
Crossref
Bjørn Kantsø, Nicola Green, David Goldblatt & Thomas Benfield. (2015) Antibody Response is More Likely to Pneumococcal Proteins Than to Polysaccharide After HIV-associated Invasive Pneumococcal Disease. Journal of Infectious Diseases 212:7, pages 1093-1099.
Crossref
Crossref
Douglas H. Yamada, Heidi Elsaesser, Anja Lux, John M. Timmerman, Sherie L. Morrison, Juan Carlos de la Torre, Falk Nimmerjahn & David G. Brooks. (2015) Suppression of Fcγ-Receptor-Mediated Antibody Effector Function during Persistent Viral Infection. Immunity 42:2, pages 379-390.
Crossref
Crossref
Michaëla A M Huson, Martin P Grobusch & Tom van der Poll. (2015) The effect of HIV infection on the host response to bacterial sepsis. The Lancet Infectious Diseases 15:1, pages 95-108.
Crossref
Crossref
Z. B. Harboe, M. V. Larsen, S. Ladelund, G. Kronborg, H. B. Konradsen, J. Gerstoft, C. S. Larsen, C. Pedersen, G. Pedersen, N. Obel & T. Benfield. (2014) Incidence and Risk Factors for Invasive Pneumococcal Disease in HIV-Infected and Non-HIV-Infected Individuals Before and After the Introduction of Combination Antiretroviral Therapy: Persistent High Risk Among HIV-Infected Injecting Drug Users. Clinical Infectious Diseases 59:8, pages 1168-1176.
Crossref
Crossref
S. Kerneis, O. Launay, C. Turbelin, F. Batteux, T. Hanslik & P.-Y. Boelle. (2014) Long-term Immune Responses to Vaccination in HIV-Infected Patients: A Systematic Review and Meta-Analysis. Clinical Infectious Diseases 58:8, pages 1130-1139.
Crossref
Crossref
James Brown & Marc Lipman. (2014) Community-Acquired Pneumonia in HIV-Infected Individuals. Current Infectious Disease Reports 16:3.
Crossref
Crossref
Lisa A. Jackson. 2013. Vaccines. Vaccines
542
572
.
Katrine M. Jensen, Jesper Melchjorsen, Frederik Dagnaes-Hansen, Uffe B. S. Sørensen, Rune R. Laursen, Lars Østergaard, Ole S. Søgaard & Martin Tolstrup. (2012) Timing of Toll-Like Receptor 9 Agonist Administration in Pneumococcal Vaccination Impacts Both Humoral and Cellular Immune Responses as Well as Nasopharyngeal Colonization in Mice. Infection and Immunity 80:5, pages 1744-1752.
Crossref
Crossref
Ching-Lan Lu, Chien-Ching Hung, Yu-Chung Chuang, Wen-Chun Liu, Chun-Ting Su, Chin-Fu Hsiao, Yu-Tzu Tseng, Yi-Ching Su, Shu-Fang Chang, Sui-Yuan Chang & Shan-Chwen Chang. (2012) Comparison of serologic responses to vaccination with one dose or two doses of 7-valent pneumococcal conjugate vaccine in HIV-infected adult patients. Vaccine 30:24, pages 3526-3533.
Crossref
Crossref
RH Pedersen, N Lohse, L Østergaard & OS Søgaard. (2011) The effectiveness of pneumococcal polysaccharide vaccination in HIV-infected adults: a systematic review. HIV Medicine 12:6, pages 323-333.
Crossref
Crossref
Alberto Cagigi, Anna Nilsson, Simone Pensieroso & Francesca Chiodi. (2010) Dysfunctional B-cell responses during HIV-1 infection: implication for influenza vaccination and highly active antiretroviral therapy. The Lancet Infectious Diseases 10:7, pages 499-503.
Crossref
Crossref
Ole S Søgaard, Henrik C Schønheyder, Anne R Bukh, Zitta B Harboe, Thomas A Rasmussen, Lars Østergaard & Nicolai Lohse. (2010) Pneumococcal conjugate vaccination in persons with HIV: the effect of highly active antiretroviral therapy. AIDS 24:9, pages 1315-1322.
Crossref
Crossref
Domenico Martinelli, Silvio Tafuri, Giovanni Caputi, Francesca Fortunato, Paolo Reggio, Cinzia Germinario & Rosa Prato. (2010) Eight years of active proposal of pneumococcal 23-valent polysaccharide vaccine: Survey on coverage rate among elderly and chronic patients. American Journal of Infection Control 38:4, pages e8-e15.
Crossref
Crossref
C‐C Hung, S‐Y Chang, C‐T Su, Y‐Y Chen, S‐F Chang, C‐Y Yang, W‐C Liu, C‐H Wu & S‐C Chang. (2009)
A 5‐year longitudinal follow‐up study of serological responses to 23‐valent pneumococcal polysaccharide vaccination among patients with HIV infection who received highly active antiretroviral therapy
*
. HIV Medicine 11:1, pages 54-63.
Crossref
Crossref
Pablo F. Belaunzarán-Zamudio, Miguel L. García-León, Rosa María Wong-Chew, Angelina Villasís-Keever, Jennifer Cuellar-Rodríguez, Juan L. Mosqueda-Gómez, Teresa Muñoz-Trejo, Kenia Escobedo, José I. Santos, Guillermo M. Ruiz-Palacios & Juan G. Sierra-Madero. (2009) Early loss of measles antibodies after MMR vaccine among HIV-infected adults receiving HAART. Vaccine 27:50, pages 7059-7064.
Crossref
Crossref
Michael L. Landrum & Matthew J. Dolan. (2008) Routine Vaccination in HIV-Infected Adults. Infectious Diseases in Clinical Practice 16:2, pages 85-93.
Crossref
Crossref
Lisa A. Jackson & Kathleen M. Neuzil. 2008. Vaccines. Vaccines
569
604
.
Philippe Lesprit, Gaëlle Pédrono, Jean-Michel Molina, Cécile Goujard, Pierre-Marie Girard, Nathalie Sarrazin, Christine Katlama, Patrick Yéni, Pascale Morineau, Jean-François Delfraissy, Geneviève Chêne & Yves Lévy. (2007) Immunological efficacy of a prime-boost pneumococcal vaccination in HIV-infected adults. AIDS 21:18, pages 2425-2434.
Crossref
Crossref
Haijun Tian, Avi Groner, Marianne Boes & Liise-anne Pirofski. (2007)
Pneumococcal Capsular Polysaccharide Vaccine-Mediated Protection against Serotype 3
Streptococcus pneumoniae
in Immunodeficient Mice
. Infection and Immunity 75:4, pages 1643-1650.
Crossref
Crossref
Mark J. Abzug, Stephen I. Pelton, Lin-Ye Song, Terence Fenton, Myron J. Levin, Sharon A. Nachman, William Borkowsky, Howard M. Rosenblatt, John F. Marcinak, Arry Dieudonne, Elaine J. Abrams & Indu Pathak. (2006) Immunogenicity, Safety, and Predictors of Response After a Pneumococcal Conjugate and Pneumococcal Polysaccharide Vaccine Series in Human Immunodeficiency Virus-Infected Children Receiving Highly Active Antiretroviral Therapy. The Pediatric Infectious Disease Journal 25:10, pages 920-929.
Crossref
Crossref
Todd D. Gleeson, Mark R. Wallace & Sybil A. Tasker. (2006) Vaccination in patients with HIV infection. Current Infectious Disease Reports 8:2, pages 151-161.
Crossref
Crossref
David Tarragó, Julio Casal, Jesús Ruiz-Contreras, J. Tomás Ramos, Pablo Rojo, Harm Snippe & Wouter T. M. Jansen. (2005) Assessment of Antibody Response Elicited by a 7-valent Pneumococcal Conjugate Vaccine in Pediatric Human Immunodeficiency Virus Infection. Clinical and Vaccine Immunology 12:1, pages 165-170.
Crossref
Crossref
Daniel R Feikin, Charles Feldman, Anne Schuchat & Edward N Janoff. (2004) Global strategies to prevent bacterial pneumonia in adults with HIV disease. The Lancet Infectious Diseases 4:7, pages 445-455.
Crossref
Crossref
D Bogaert, P.W.M Hermans, P.V Adrian, H.C Rümke & R de Groot. (2004) Pneumococcal vaccines: an update on current strategies. Vaccine 22:17-18, pages 2209-2220.
Crossref
Crossref
Allyn K. Nakashima & Ida M. Onorato. 2004. AIDS and Other Manifestations of HIV Infection. AIDS and Other Manifestations of HIV Infection
947
971
.
M. C. Rodriguez-Barradas, I. Alexandraki, T. Nazir, M. Foltzer, D. M. Musher, S. Brown & J. Thornby. (2003) Response of Human Immunodeficiency Virus-Infected Patients Receiving Highly Active Antiretroviral Therapy to Vaccination with 23-Valent Pneumococcal Polysaccharide Vaccine. Clinical Infectious Diseases 37:3, pages 438-447.
Crossref
Crossref
Sybil A. Tasker, Mark R. Wallace, Jeffrey B. Rubins, William B. Paxton, James O Brien & Edward N. Janoff. (2002) Reimmunization with 23-Valent Pneumococcal Vaccine for Patients Infected with Human Immunodeficiency Virus Type 1: Clinical, Immunologic, and Virologic Responses. Clinical Infectious Diseases 34:6, pages 813-821.
Crossref
Crossref
V. Falcó Ferrer, O. Len Abad & A. Pahissa Berga. (2002) Vacuna neumocócica en los pacientes con infección por el virus de la inmunodeficiencia humana. Revista Clínica Española 202:7, pages 395-398.
Crossref
Crossref
Anna B. Pierce & Jennifer F. Hoy. (2001) Is the recommendation for pneumococcal vaccination of HIV patients evidence based?. Journal of Clinical Virology 22:3, pages 255-261.
Crossref
Crossref
Joel Witter. (2001) Primary Care of the HIV-Infected Patient. Primary Care Case Reviews 4:3, pages 142-153.
Crossref
Crossref
Å. Örtqvist. (2001) Pneumococcal vaccination: current and future issues. European Respiratory Journal 18:1, pages 184-195.
Crossref
Crossref
Richard A. Proctor. (2001) Bacterial sepsis in patients with acquired immunodeficiency syndrome. Critical Care Medicine 29:3, pages 683-684.
Crossref
Crossref
Rosemary Dray-Spira, Philippe Lepage & François Dabis. (2000) Prevention of infectious complications of paediatric HIV infection in Africa. AIDS 14:9, pages 1091-1099.
Crossref
Crossref
Sybil A. Tasker & Mark R. Wallace. (2000) Vaccination in HIV-infected patients. Current Infectious Disease Reports 2:3, pages 247-256.
Crossref
Crossref
Joseph A. Kovacs & Henry Masur. (2000) Prophylaxis against Opportunistic Infections in Patients with Human Immunodeficiency Virus Infection. New England Journal of Medicine 342:19, pages 1416-1429.
Crossref
Crossref
JUHANI ESKOLA. (2000) Immunogenicity of pneumococcal conjugate vaccines. The Pediatric Infectious Disease Journal 19:4, pages 388-393.
Crossref
Crossref